Hoechst Pakistan Limited

HPL

PK0021801011

Pharmaceuticals

End-of-day quote Pakistan S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
1,320 ^PKR	-2.24%		-5.56%	+9.98%

Mar. 18	Hoechst Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Hoechst Pakistan Limited Announces Company Secretary Changes	CI

Sanofi-Aventis Pakistan Limited Recommends Final Cash Dividend for the Year Ended December 31, 2020

March 02, 2021 at 06:30 am EST

Sanofi-Aventis Pakistan Limited announced that the board of directors of the company in their meeting held on March 2, 2021 recommended a final cash dividend for the year ended December 31, 2020 at PKR 20.00 per share that is 200%.

Latest news about Hoechst Pakistan Limited

Hoechst Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 17	CI
Hoechst Pakistan Limited Announces Company Secretary Changes	Nov. 01	CI
Hoechst Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Oct. 31	CI
Sanofi-aventis Pakistan Limited will Change its Name to Hoechst Pakistan Limited	23-09-05	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-28	CI
Sanofi-aventis Pakistan Limited Announces CEO Changes	23-06-13	CI
Sanofi-aventis Pakistan Limited Announces Retirement of Dr. Asim Jamal as Managing Director, Effective June 30, 2023	23-06-13	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-02	CI
Sanofi Aventis Pakistan Limited Announces Change of Directors	23-05-01	CI
The Investor Consortium comprised of Packages Limited, IGI Investments Limited and Ali Gohar & Co. Ltd completed the acquisition of 52.87% stake in sanofi-aventis Pakistan Limited from Sanofi Foreign Participations B.V.	23-04-27	CI
Pakistan defers decision on drug price rise as pharma firms struggle	23-03-27	RE
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-29	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-31	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-10-27	CI
Sanofi-Aventis Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-28	CI
Sanofi-Aventis Pakistan Limited Recommends Final Cash Dividend for the Year Ended December 31, 2020	21-03-02	CI
Sanofi-Aventis Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-02	CI
Sanofi-Aventis Pakistan Limited Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-10-27	CI
Sanofi-Aventis Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2020	20-04-29	CI
Sanofi-Aventis Pakistan Limited Recommends Final Cash Dividend for the Year Ended December 31, 2019	20-03-03	CI
Sanofi-Aventis Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-03	CI
Sanofi Aventis Pakistan Limited Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-10-28	CI

Chart Hoechst Pakistan Limited

Duration

Period

More charts

Company Profile

Hoechst Pakistan Limited, formerly Sanofi Aventis Pakistan Limited, is a pharmaceutical company, which is engaged in the manufacturing and selling of pharmaceutical and consumer products. It offers medicines, consumer healthcare products, generics and animal health products. Its products for diabetes include Amaryl, Amaryl MSR, Daonil, Neodipar, Toujeo, Lantus, SoloSTAR and Apidra. Its oncology products include Thyrogen, Jevtana, Taxotere, Eloxatin and Fludara. Its nephrology product is Renvela. Its organ transplantation is Thymoglobuline. Its urology product is Xatral. Its pain management products are No-Spa and Muscoril. Its antiemetic product includes Stemetil. Its allergy management product includes Telfast, Telfast-D, Avil, Nasacort, Phenergan and Tixylix. Its sleep disorder product is Stilnox. Its other products include Haemaccel, Plavix, CoPlavix, Aprovel, CoAprovel, Cordarone, Clexane, Tritace, CoTritace, Winstor, Lasix, Flagyl, Tarivid, Claforan, Aventriax, Orelox, and others.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HOECHST PAKISTAN LIMITED	+9.98%	45.71M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B